To prepare an eye drop solution useful for treating symptoms caused by an allergy or a vasomotor nerve or a nasal virus by making the eye drop solution include azelastine therein.

This eye drop solution contains 0.0005-2% (wt./wt.) azelastine, which may be present in the form of a physiologically compatible salt and further a pharmaceutically usable preservative in an amount of 0.001-0.1% (weight per volume of a solution in the case of the solution and weight per weight of a formulation in the case of the solid formulation). The solution is an aqueous solution and sodium 2-(ethylmercurithio)-benzoate in an amount of 0.001-0.05% (wt./vol. of the solution) or an alkylbenzylmethylammonium chloride in an amount of 0.001-0.1% (wt./vol. of the solution) is especially preferably contained.